Drug
Recombinant FVIIa clinical trials
Also written activated recombinant human factor VII and NovoSeven.
- studies test it
- 59
- open now
- 4
- in phase 3
- 14
- first study started
- 1998
Keep track of what changes. Save the recombinant FVIIa studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
58 studies that test it; most in 2005 (9)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 1 |
| 2001 | 8 |
| 2002 | 7 |
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 24
- Phase 3
- 14
- Phase 4
- 6
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 42 · Other 17
Novo Nordisk A/S (36) · Joseph Broderick, MD (2) · Laboratoire français de Fractionnement et de Biotechnologies (2) · rEVO Biologics (2) · Sheba Medical Center (2) · Janssen Research & Development, LLC (1) · AryoGen Pharmed Co. (1) · Dr. David Gladstone (1)
Often tested with
Tested in the same studies.
Vatreptacog alfa (2) · Four-factor Prothrombin Complex Concentrate (1) · Factor VIII (1) · Biosimilar Pharmaceuticals (1) · Warfarin (1) · Anti-inhibitor coagulant complex (1) · Prothrombin complex concentrate (1)
Studies
Open first, then newest update. How each study uses recombinant FVIIa is read from its arms, and is right about nine times in ten.
Testing it · 59
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaRecruitingPhase 4Novo Nordisk A/SNCT07157423Written as Eptacog alfa (NovoSeven)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2RecruitingPhase 3Joseph Broderick, MDNCT07227246Written as Recombinant Factor VIIa
- SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsRecruitingPhase 4American Thrombosis and Hemostasis NetworkNCT04647227Written as coagulation factor VIIa [recombinant]-jncw
- Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)RecruitingPhase 2Emory UniversityNCT07136857Written as EPTACOG BETA
- Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major SurgeryTerminatedPhase 3Laboratoire français de Fractionnement et de BiotechnologiesNCT05695391Written as Coagulation Factor VIIa (Recombinant)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke TrialActive, not recruitingPhase 3Joseph Broderick, MDNCT03496883Written as Recombinant Activated Factor VII (rFVIIa)
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04543383Written as Recombinant Human Factor VIIa (rFVIIa)
- Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedPhase 4Novo Nordisk A/SNCT01561391Written as activated recombinant human factor VII
- LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive ProceduresCompletedPhase 3Laboratoire français de Fractionnement et de BiotechnologiesNCT02548143Written as Coagulation Factor VIIa (Recombinant)
- Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII DeficiencyCompletedPhase 3AryoGen Pharmed Co.NCT03079063Written as Eptacog alfa, biosimilar
- "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic TherapyCompletedPhase 2Dr. David GladstoneNCT01359202Written as rfVIIa
- The Spot Sign for Predicting and Treating ICH Growth StudyCompletedPhase 2University of CincinnatiNCT00810888Written as recombinant activated factor VII
- Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With InhibitorsCompletedPhase 3rEVO BiologicsNCT02020369Written as Coagulation Factor VIIa (Recombinant)
- Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedPhase 3Novo Nordisk A/SNCT01392547Written as eptacog alfa (activated)
- Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCompletedPhase 2Novo Nordisk A/SNCT00486278Written as eptacog alfa (activated)
- Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedPhase 2Novo Nordisk A/SNCT01564563Written as activated recombinant human factor VII
- Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedPhase 1Novo Nordisk A/SNCT01561417Written as activated recombinant human factor VII
- Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedPhase 2Novo Nordisk A/SNCT00426803Written as activated recombinant human factor VII
- Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionCompletedPhase 2Novo Nordisk A/SNCT01601457Written as activated recombinant human factor VII
- Use of NovoSeven® in Active Variceal BleedingCompletedPhase 2Novo Nordisk A/SNCT00154492Written as activated recombinant human factor VII
See all 59 studies that test recombinant FVIIa →
Given in every arm · 3 — recombinant FVIIa is usual care beside what is tested
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingPhase 3Emory UniversityNCT04563520Written as rFVIIa
- A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsCompletedPhase 2Novo Nordisk A/SNCT03196284Written as Eptacog alfa
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02622321Written as rFVIIa
As the comparator · 3 — what is tested is compared with recombinant FVIIa
- Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With InhibitorsCompletedPhase 3AryoGen Pharmed Co.NCT03935334Written as Eptacog alfa, activated (Novoseven)
- Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With InhibitorsTerminatedPhase 2/3CSL BehringNCT02484638Written as Eptacog alfa (activated)
- A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150CompletedPhase 2/3BayerNCT01625390Written as eptacog alfa [activated]
Codes
What other systems call recombinant FVIIa · ClinicalTrials.gg INT003954
- MeSH (NLM) C103587recombinant FVIIaOne source NLM
- UNII (FDA) AC71R787OVCOAGULATION FACTOR VIIA RECOMBINANT HUMANConfirmed FDA, NLM
- RxNorm 253149One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C103587 | recombinant FVIIa | One source NLM |
| UNII (FDA) | AC71R787OV | COAGULATION FACTOR VIIA RECOMBINANT HUMAN | Confirmed FDA, NLM |
| RxNorm | 253149 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.